Majida MA, a lawyer from Kerala, is fighting a landmark legal battle to ensure access to life-saving breast cancer medication that costs her a staggering ₹80,000 per month.
- Kerala lawyer Majida MA is facing extreme financial hardship due to ₹80,000 monthly cancer drug costs.
- The Kerala High Court has converted a related case into a Public Interest Litigation (PIL).
- The legal battle seeks to use Patent Act provisions to facilitate access to affordable generic medicines.
For 49-year-old Majida MA, a practicing lawyer from Kerala, survival is measured in milligrams and monthly bills. Every morning, she takes three tablets of ribociclib—a targeted therapy drug sold as Kryxana in India—to keep her breast cancer at bay. However, the cost of this lifeline is nearly crushing her financial stability.
The financial burden is immense. Each strip of 21 pills costs approximately ₹25,000, leading to a monthly expenditure of ₹75,000 to ₹80,000. For a practicing lawyer supporting two children in college and elderly parents, these costs are unsustainable. The situation is exacerbated by recent denials of health insurance claims, forcing her to pay entirely out of pocket.
Why This Matters
BozokMedia analysis shows that this case highlights a critical systemic failure where patent protections for pharmaceutical giants clash directly with the fundamental right to life and health. As drug prices escalate, the gap between medical innovation and medical accessibility continues to widen for the middle class.
The question is not whether the medicine exists, but whether the price determines who survives.
The legal battle, now a Public Interest Litigation (PIL) in the Kerala High Court, seeks to leverage the Patents Act. The petition explores whether the government can issue compulsory licenses to generic manufacturers during health crises to ensure affordability. The Supreme Court has also taken interest, directing an expedited resolution.
The Medical Dilemma
A significant point of debate in court is the interchangeability of drugs. While cheaper generic versions of palbociclib exist, medical experts caution against simple substitution. Dr. R Ravi Kannan, Director of Cachar Cancer Hospital, notes that while palbociclib is effective for metastatic cancer, ribociclib has shown superior benefits in disease-free survival for early-stage patients.
| Feature | Ribociclib (Kryxana) | Palbociclib (Generic) |
|---|---|---|
| Monthly Cost | High (~₹80,000) | Relatively Low |
| Clinical Advantage | High efficacy in early-stage | Proven in metastatic stages |
| Legal Status | Patented/Expensive | Generic/Accessible |
Frequently Asked Questions
1. What is the core issue in the Kerala High Court PIL?
The core issue is how to provide affordable access to patented, life-saving cancer drugs through legal mechanisms like compulsory licensing.
2. Can cheaper drugs be used instead of ribociclib?
While cheaper drugs like palbociclib exist, they may not provide the same clinical benefits for all stages of breast cancer.
